Maxim Group analyst Jason McCarthy maintained a Buy rating on Co-Diagnostics (CODX – Research Report) yesterday and set a price target of $2.00. The company’s shares closed last Monday at $1.01, close to its 52-week low of $0.69.
According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -20.1% and a 28.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Hancock Jaffe Laboratories, and Lineage Cell Therapeutics.
Currently, the analyst consensus on Co-Diagnostics is a Moderate Buy with an average price target of $2.00.
The company has a one-year high of $3.77 and a one-year low of $0.69. Currently, Co-Diagnostics has an average volume of 86.24K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company’s products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules.